Brain immunology and immunotherapy in brain tumours
John H Sampson 1 2, Michael D Gunn 3, Peter E Fecci 4 5 6, David M Ashley 4Affiliations expand
- PMID: 31806885
- PMCID: PMC7327710 (available on 2021-01-01)
- DOI: 10.1038/s41568-019-0224-7
Abstract
Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet, seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of the immune system within the central nervous system (CNS) and altered the paradigm for successful immunotherapy. The impact of standard therapies on the response to immunotherapy is now better understood, as well. This new knowledge has implications for a broad range of tumours that develop within the CNS. Nevertheless, the requirements for successful therapy remain effective delivery and target specificity, while the dramatic heterogeneity of malignant gliomas at the genetic and immunological levels remains a profound challenge.
